Sandoz Group AG (SDZNY) Stock Price & Analysis
Sandoz Group AG (SDZNY) — price $82.86 (+0.34%), as of the Oct 2, 2026 trading session; market cap $35.9B.
Educational signal · not a buy or sell recommendation · How to read this
Sandoz Group AG · SDZNY · Healthcare · Drug Manufacturers - Specialty & Generic
Research dated 2026-09-12: Sandoz develops, manufactures and markets generic medicines and biosimilars across a broad therapeutic portfolio, alongside active pharmaceutical ingredients and finished dosage forms. The case rests on whether stronger sales and operating cash generation can translate into durable net profitability while the company funds its investment cycle and carries debt well above liquid assets.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $82.86 | |
| Change on the day | +0.34% | |
| 52-week range | $59.27 – $94.15 | |
| Market capitalisation | $35.9B | |
| Price / earnings (trailing) | 55.36 | |
| Shares traded on the day | 429 | |
| Beta (volatility vs the S&P 500) | 0.49 | |
| Dividends per share (last 12 months) | $1.02 | |
| Dividend yield (last 12 months) | 1.23% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Management outlook
Again, we still have the ambition that we will get an approval and launch in Canada this year.
Richard Saynor · Statement from
We continue to expect CapEx to peak during the current investment cycle this year at around USD 1.1 billion.
Remco Steenbergen · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations can change.
Read management statementsOther perspectives
Council score for Sandoz Group AG (SDZNY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Jul 13, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Jul 13, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the SDZNY film — every key number, told as a short cinematic story
~2 min · open the film
What is Sandoz Group AG (SDZNY), and what does it report?
Short answer · as of
Sandoz is not a conventional branded-drug discovery company. Its reported sales combine generic medicines, biosimilars, active pharmaceutical ingredients and finished dosage forms sold across many therapeutic areas, so changes in portfolio mix can affect gross profit and operating profit differently from revenue.
Research dated 2026-09-12.
Sandoz is not a conventional branded-drug discovery company. Its reported sales combine generic medicines, biosimilars, active pharmaceutical ingredients and finished dosage forms sold across many therapeutic areas, so changes in portfolio mix can affect gross profit and operating profit differently from revenue.
The reporting record shows a broad pharmaceutical manufacturer whose research spending, commercial costs and manufacturing investment all sit between sales and net income. That distinction matters because recent operating improvement has not always carried through proportionately to the bottom line.
What do the latest results show for Sandoz Group AG (SDZNY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $5.77B.
Research dated 2026-09-12.
The latest reported period kept revenue above the comparable prior period but below the immediately preceding period. Gross profit and operating profit followed a similar pattern, while net income and diluted earnings weakened much more sharply, showing that operating progress did not fully reach shareholders.
Operating cash flow strengthened near the top of the displayed series even as capital expenditure increased. Management separately expects currency movements to support sales and says capital expenditure should peak during the current investment cycle; those statements frame the outlook but do not explain the reported decline in net income.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $5.77B Jun 30, 2026
- Latest quarter · R&D
- $512.11M Jun 30, 2026
- Latest quarter · SG&A
- $1.37B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $812.76M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $5.77B | $512.11M | $1.37B | $812.76M |
| Dec 31, 2025 | $5.85B | $545.59M | $1.34B | $1.02B |
| Jun 30, 2025 | $5.26B | $503.25M | $1.19B | $601.11M |
| Dec 31, 2024 | $5.32B | $468.58M | $1.19B | −$24.98M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $7.38B Mar 3, 2026
- Latest report · revenue estimate
- $2.78B Mar 3, 2026
- Latest report · revenue vs estimate
- Above estimate Mar 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Mar 3, 2026 | $7.38B | $2.78B | $1.5800 | Not available |
| Aug 7, 2025 | $5.26B | $2.85B | $0.8640 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $5.77B | $109M | $0.25 (diluted) |
| Q4 FY2025 | $5.85B | $537M | $1.24 (diluted) |
| Q2 FY2025 | $5.26B | $376M | $0.87 (diluted) |
| Q4 FY2024 | $5.32B | -$150M | -$0.35 (diluted) |
What are the financial strengths and risks for Sandoz Group AG (SDZNY)?
Short answer
Cash and short-term investments were $1.25B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $872.89M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Positive operating cash flow across the displayed periods, with marked recent improvement, gives Sandoz internal funding capacity during a capital-intensive phase. Cash and short-term investments have also risen substantially from the earliest displayed balances, although they retreated from the preceding period.
Debt remains far above cash and investments, leaving the company in a net-debt position. Near-term liquidity is adequate only narrowly on the current-ratio measure and weaker on the quick-ratio measure, while the modest net margin shows how much operating profit is lost before reaching net income. A reversal in cash conversion during peak investment spending would therefore put more pressure on financial flexibility.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $872.89M Jun 30, 2026
- Previous quarter · operating cash flow
- $843.67M Dec 31, 2025
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $872.89M | −$266.58M |
| Dec 31, 2025 | $843.67M | −$227.89M |
| Jun 30, 2025 | $522.22M | −$202.70M |
| Dec 31, 2024 | $426.62M | −$238.79M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Sandoz Group AG (SDZNY)?
Research dated 2026-09-12.
Watch whether revenue resumes sequential growth, whether operating profit converts more consistently into net income, and whether operating cash flow continues to cover elevated capital expenditure. Consensus expectations call for further sales and earnings expansion, making the gap between operating performance and net earnings especially important.
Management has identified a planned Canadian approval and launch, a peak in the current capital-spending cycle and favorable currency movement as near-term markers. Progress on the launch, evidence that investment spending is cresting, and cash retention after that spending would each test a different part of the operating case.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Again, we still have the ambition that we will get an approval and launch in Canada this year.
Richard Saynor ·
We continue to expect CapEx to peak during the current investment cycle this year at around USD 1.1 billion.
Remco Steenbergen ·
Outside of guidance, we now anticipate a 2 percentage points tailwind to net sales from currency movement this year based on recent spot rates and average rates in the period.
Remco Steenbergen ·
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is Sandoz Group AG scored?
Research dated 2026-09-12.
Sandoz combines conventional generic medicines with biosimilars and also supplies active pharmaceutical ingredients and finished dosage forms. That breadth differs from a business concentrated solely on novel branded drugs or solely on finished generic products: product mix, manufacturing execution and commercial uptake operate across several pharmaceutical formats.
The market valuation places a substantial price on earnings despite a much lower net margin than operating margin. Recent dividend increases and improving cash generation add evidence of financial progression, but the net-debt position means comparisons based only on sales growth miss an important balance-sheet difference.
| Company | Price | Market value | Score |
|---|---|---|---|
| $12.64 Oct 2, 2026 | $49.7B | — Model unavailable | |
| $54.35 Oct 2, 2026 | $30.6B | — Model unavailable | |
| $4.46 Oct 2, 2026 | $39.3B | — Model unavailable | |
| $4.38 Oct 2, 2026 | $14.0B | — Model unavailable | |
| $73.16 Oct 2, 2026 | $38.4B | — Model unavailable | |
| $69.69 Oct 2, 2026 | $29.2B | — 5-pillar · not comparable | |
| $39.53 Oct 2, 2026 | $46.0B | — 5-pillar · not comparable | |
| $17.86 Oct 2, 2026 | $56.8B | — 5-pillar · not comparable | |
| $17.60 Oct 2, 2026 | $20.5B | — 5-pillar · not comparable | |
| $22.14 Oct 2, 2026 | $11.1B | — 5-pillar · not comparable | |
| $12.25 Oct 2, 2026 | $10.2B | — 5-pillar · not comparable | |
| $99.96 Oct 2, 2026 | $6.51B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.1% Period end Jun 30, 2026
- Previous quarter · ownership
- 0.1% Prior to period end Jun 30, 2026
- Reporting holders
- 29 Period end Jun 30, 2026
- Previous quarter · holders
- 32 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Ramirez Asset Management, INC. | 121,190 |
| Henry James International Management INC. | 64,767 |
| Confluence Investment Management LLC | 27,141 |
| Delphi Management INC /Ma/ | 16,081 |
| Rhumbline Advisers | 10,034 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Sandoz Group AG (SDZNY)?
Common Questions About SDZNY (Healthcare)
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Sandoz sell besides generic medicines?
Sandoz also develops and markets biosimilars and provides active pharmaceutical ingredients and finished dosage forms. Its portfolio reaches across numerous therapeutic areas rather than relying on a narrowly defined disease franchise.
Are Sandoz earnings keeping pace with its recent revenue performance?
Recent revenue remained above the comparable prior period, but net income weakened sharply while operating profit held up better. The divergence makes conversion from operating profit to net earnings a key measure of progress.
Can Sandoz fund its current investment cycle from operations?
Recent operating cash flow exceeded capital expenditure, providing internal funding for the current investment phase. Continued coverage matters because management expects capital spending to crest while debt remains well above liquid assets.
How do biosimilars change the Sandoz business mix?
Biosimilars sit alongside generic medicines, ingredients and finished dosage forms, giving Sandoz exposure to more than a uniform generic-product stream. The resulting mix means revenue alone cannot show whether gross profit, operating profit and net income are improving together.
What is the SDZNY stock price today?
The last price recorded on this page for Sandoz Group AG (SDZNY) is $82.86, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does SDZNY pay a dividend?
Yes. Sandoz Group AG (SDZNY) shows a trailing 12-month dividend yield of 1.23%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (64 figures)
The 64 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Richard Saynor (Aug 5, 2026): Again, we still have the ambition that we will get an approval and launch in Canada this year. Remco Steenbergen (Aug 5, 2026): We continue to expect CapEx to peak during the current investment cycle this year at around USD 1.1 billion. Remco Steenbergen (Aug 5, 2026): Outside of guidance, we now anticipate a 2 percentage points tailwind to net sales from currency movement this year based on recent spot rates and average rates in the period. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 58 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $82.86 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T17:14:23.235Z. | |
px.change | Change on the day | +0.34% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $35.9B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T17:14:22.358Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.283 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 55.36 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 429 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.49 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Richard Saynor | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 23,000 | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Centralbahnstrasse 4, Basel, ZG, 4051, CH | FMP | Financial Modeling Prep (FMP) company profile | |
fin.q_revenue | Revenue, Q2 FY2026 | $5.77B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $9.62B, net result $907.82M; FY2022 revenue $9.30B, net result $847.75M; FY2023 revenue $11.66B, net result $89.99M; FY2024 revenue $10.38B, net result $1.00M; FY2025 revenue $11.15B, net result $919.12M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 47.5% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $5.77B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $512.11M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $1.37B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $812.76M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $5.85B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $545.59M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $1.34B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $1.02B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.revenue_k | Revenue — period end 2025-06-30 | $5.26B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.rd_k | R&D — period end 2025-06-30 | $503.25M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.sga_k | SG&A — period end 2025-06-30 | $1.19B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.operating_result_k | FMP standardized operating result — period end 2025-06-30 | $601.11M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.revenue_k | Revenue — period end 2024-12-31 | $5.32B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.rd_k | R&D — period end 2024-12-31 | $468.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.sga_k | SG&A — period end 2024-12-31 | $1.19B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.operating_result_k | FMP standardized operating result — period end 2024-12-31 | −$24.98M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-03-03.revenue_actual | Revenue · reported — report date 2026-03-03 | $7.38B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.revenue_estimated | Revenue · estimate — report date 2026-03-03 | $2.78B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-03.eps_actual | EPS · reported — report date 2026-03-03 | $1.5800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-07.revenue_actual | Revenue · reported — report date 2025-08-07 | $5.26B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-07.revenue_estimated | Revenue · estimate — report date 2025-08-07 | $2.85B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-07.eps_actual | EPS · reported — report date 2025-08-07 | $0.8640 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.25B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $872.89M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $47.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $6.20B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.98× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $872.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $843.67M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$266.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$227.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.operating_cash_flow_m | Operating cash flow — period end 2025-06-30 | $522.22M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.capex_m | Capital expenditure (reported) — period end 2025-06-30 | −$202.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.operating_cash_flow_m | Operating cash flow — period end 2024-12-31 | $426.62M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.capex_m | Capital expenditure (reported) — period end 2024-12-31 | −$238.79M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
own.institutions.depth.ownership_pct | Institutional ownership | 0.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 0.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 29 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 32 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Ramirez Asset Management, INC. — shares in provider snapshot | 121,190 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Henry James International Management INC. — shares in provider snapshot | 64,767 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Confluence Investment Management LLC — shares in provider snapshot | 27,141 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Delphi Management INC /Ma/ — shares in provider snapshot | 16,081 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Rhumbline Advisers — shares in provider snapshot | 10,034 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 1 fact from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $59.27 – $94.15 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.02 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 1.23% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-03-03.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($7.38B) with the recorded estimate ($2.78B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 28.72× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $1.25B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-06-30.revenue_k,fin.q_table.depth.2025-06-30.rd_k,fin.q_table.depth.2025-06-30.sga_k,fin.q_table.depth.2025-06-30.operating_result_k,fin.q_table.depth.2024-12-31.revenue_k,fin.q_table.depth.2024-12-31.rd_k,fin.q_table.depth.2024-12-31.sga_k,fin.q_table.depth.2024-12-31.operating_result_k. - Earnings-history note. Source series as of 2026-03-03. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-03-03.revenue_actual,earn.history.depth.2026-03-03.revenue_estimated,earn.history.depth.2026-03-03.revenue_actual.comparison,earn.history.depth.2026-03-03.eps_actual,earn.history.depth.2025-08-07.revenue_actual,earn.history.depth.2025-08-07.revenue_estimated,earn.history.depth.2025-08-07.eps_actual. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-06-30.operating_cash_flow_m,fin.opcf.depth.2025-06-30.capex_m,fin.opcf.depth.2024-12-31.operating_cash_flow_m,fin.opcf.depth.2024-12-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $6.20B; Liquidity basis: cash and short-term investments; Total liabilities: $13.79B; Cash and short-term investments: $1.25B; Cash and investments: $1.30B; Long-term investments: $47.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$4.95B; Total debt: $6.20B; Cash and investments: $1.25B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Management outlook — dated call excerpts | Captured record · 3 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-05 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - Specialty & Generic | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 2 quarters | Captured record · 2 entries
| 2026-03-03 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.30B; Cash and short-term investments: $1.25B; Long-term investments: $47.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Trailing twelve-month ratio set | Quick ratio: 0.72; Current ratio: 1.05; Debt to equity: 0.69; Net margin: 5.6%; Gross margin: 47.5%; Operating margin: 15.8%; Return on assets: 2.8%; Return on equity: 7% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 3.4; Piotroski F-score: 4 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Recent dividends paid | Captured record · 3 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-04-14 | FMP | Financial Modeling Prep (FMP) dividend history |
Data provided for informational purposes only.